AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12860337 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraamniotic prostaglandin E2 (PGE2) applied in serial doses of 200 mcg every 2 h up to 20 doses.
Number of subjects: 262
Study 12860337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of oxytocin added when fetus was not expelled.
Number of subjects: 262
Study 12860337 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage performed in the majority of patients.
Number of subjects: 262
Study 12860337 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without a uterine scar).
Number of subjects: 262
Study 10923280 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day for 12 weeks
Number of subjects: 244
Study 10923280 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day for 12 weeks
Number of subjects: 244
Study 10923280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 8638517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm hydrogen sulfide (H2S) inhalation
Number of subjects: 25
Study 8638517 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm (control)
Number of subjects: 25
Study 1433583 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (reimplantation)
Number of subjects: 151
Study 2578653 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular synchronous pacing
Number of subjects: 44
Study 2578653 — intervention group
Group type: COMPARATOR
Intervention: Ventricular inhibited pacing
Number of subjects: 44
Study 31254596 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg/day for 3 weeks
Number of subjects: 20
Study 31254596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29283177 — intervention group
Group type: EXPERIMENTAL
Intervention: UAB criteria (AVF outflow vein lumen diameter ≥4 mm and blood flow ≥500 mL/min)
Number of subjects: 105
Study 29283177 — intervention group
Group type: COMPARATOR
Intervention: NKF criteria (AVF outflow vein lumen diameter ≥6 mm and blood flow ≥600 mL/min)
Number of subjects: 105
Study 29283177 — intervention group
Group type: EXPERIMENTAL
Intervention: UAB criteria for radiocephalic AVFs
Number of subjects: 105
Study 29283177 — intervention group
Group type: EXPERIMENTAL
Intervention: UAB and NKF criteria for brachiocephalic AVFs
Number of subjects: 105
Study 26750378 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse PM (164.2 ± 80.4 μg/m(3))
Number of subjects: 29
Study 26750378 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 29
Study 25336193 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent plus palliative radiotherapy (20 Gy in five fractions over one week or 30 Gy in 10 fractions over two weeks)
Number of subjects: 496
Study 25336193 — intervention group
Group type: COMPARATOR
Intervention: Stent alone
Number of subjects: 496
Study 21691139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 20
Study 21691139 — intervention group
Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 20
Study 20838372 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg kg‐1)
Number of subjects: 90
Study 20838372 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.2 mg kg‐1)
Number of subjects: 90
Study 20838372 — intervention group
Group type: COMPARATOR
Intervention: Control (0.1 mL kg‐1 saline)
Number of subjects: 90
Study 17949392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 812
Study 17949392 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 812
Study 17949392 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-step facilitation (TSF)
Number of subjects: 812
Study 17949392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 812
Study 16055638 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian participants
Number of subjects: 0
Study 16055638 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese participants
Number of subjects: 0
Study 12153738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX), 0.1 mg twice daily for 3 days
Number of subjects: 0
Study 12153738 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal at 0, 24, 36 and 48 h
Number of subjects: 0
Study 12153738 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal at 0 and 48 h
Number of subjects: 0
Study 12153738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 48 h
Number of subjects: 0
Study 12153738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DEX)
Number of subjects: 0
Study 10343536 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm‐MDP bone scintigraphy
Number of subjects: 58
Study 9035660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal douche (saline solution)
Number of subjects: 36
Study 9035660 — intervention group
Group type: COMPARATOR
Intervention: Hand irrigation (saline solution)
Number of subjects: 36
Study 1820757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation for 2 weeks
Number of subjects: 30
Study 1820757 — intervention group
Group type: COMPARATOR
Intervention: Lithium augmentation for 4 weeks
Number of subjects: 30
Study 6366345 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Indomethacin solution, 1 drop 4 times daily for 3 months
Number of subjects: 0
Study 6366345 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 drop 4 times daily for 3 months
Number of subjects: 0
Study 31480637 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dietary fat intake (varied in saturated, polyunsaturated, and monounsaturated fatty acid composition)
Number of subjects: 218
Study 31480637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dietary fat intake (MUFA-rich meals)
Number of subjects: 218
Study 31480637 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial MUFA-rich meals
Number of subjects: 218
Study 29568003 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (28g)
Number of subjects: 27
Study 29568003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-caseinate (28g)
Number of subjects: 27
Study 29568003 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (27g)
Number of subjects: 27
Study 26965317 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed clamping of the umbilical cord (≥180 s after delivery)
Number of subjects: 0
Study 26965317 — intervention group
Group type: COMPARATOR
Intervention: Early clamping of the umbilical cord (≤60 s)
Number of subjects: 0
Study 23192897 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx)
Number of subjects: 40
Study 23192897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 23192897 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (Asx) and Placebo (P)
Number of subjects: 40
Study 21388398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormones secreted by the pituitary gland
Number of subjects: 0
Study 21388398 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasing factors characterized as peptides
Number of subjects: 0
Study 21388398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical use of neuroendocrinology findings
Number of subjects: 0
Study 21388398 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration of ubiquity of releasing factors
Number of subjects: 0
Study 21388398 — intervention group
Group type: EXPERIMENTAL
Intervention: Implications in control of behavior
Number of subjects: 0
Study 19880578 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine lozenge
Number of subjects: 270
Study 17009067 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (4-6 IU/hour for 3-5 days)
Number of subjects: 28
Study 17009067 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion + pioglitazone (15 mg/day)
Number of subjects: 28
Study 17009067 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion without pioglitazone
Number of subjects: 28
Study 15497603 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic interventions
Number of subjects: 0
Study 15497603 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect
Number of subjects: 0
Study 11050517 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 24
Study 11050517 — intervention group
Group type: COMPARATOR
Intervention: S-IMV/PSV
Number of subjects: 24
Study 11050517 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 24
Study 9062089 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 120
Study 9062089 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary angioplasty
Number of subjects: 120
Study 8398325 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tetracycline pleurodesis
Number of subjects: 34
Study 8398325 — intervention group
Group type: COMPARATOR
Intervention: Medical tetracycline pleurodesis
Number of subjects: 34
Study 8398325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical and medical tetracycline pleurodesis
Number of subjects: 34
Study 2878025 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing administration sets every 24 h
Number of subjects: 387
Study 2878025 — intervention group
Group type: COMPARATOR
Intervention: Changing administration sets every 120 h
Number of subjects: 387
Study 30558592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined neuromuscular exercise and back care counseling
Number of subjects: 219
Study 30558592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 219
Study 30558592 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 219
Study 30558592 — intervention group
Group type: COMPARATOR
Intervention: No intervention Control
Number of subjects: 219
Study 27057222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar sodium lactate (HSL)
Number of subjects: 60
Study 27057222 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 3% (HSS)
Number of subjects: 60
Study 25470094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 505
Study 25470094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 22842368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise training (15 weeks, 2 sessions per week of walking and 2 sessions per week of resistance training)
Number of subjects: 29
Study 22842368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study 20566009 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus zoledronic acid (4 mg intravenously every 3 months)
Number of subjects: 200
Study 20566009 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 200
Study 18954634 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless bioprostheses (group A)
Number of subjects: 62
Study 18954634 — intervention group
Group type: COMPARATOR
Intervention: Stented bioprostheses (group B)
Number of subjects: 62
Study 19368963 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) score treatment
Number of subjects: 586
Study 14685645 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 74
Study 14685645 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 74
Study 11772961 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral baclofen
Number of subjects: 20
Study 11772961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9466096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 96
Study 9466096 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.4 mg kg‐1
Number of subjects: 96
Study 7930718 — intervention group
Group type: EXPERIMENTAL
Intervention: gp160-recombinant vaccinia virus (HIVAC-1e) followed by recombinant (r) gp160 boosting
Number of subjects: 29
Study 7930718 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVAC-1e-primed vaccinees
Number of subjects: 29
Study 3335729 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit training alone
Number of subjects: 15
Study 3335729 — intervention group
Group type: COMPARATOR
Intervention: Habit training and placebo
Number of subjects: 15
Study 3335729 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit training and oxybutynin (2.5 mg three times daily for 1 week, then 5 mg three times daily for 1 week)
Number of subjects: 15
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 24
Study 11317473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31142294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (aerobic and strength) three times per week for 12 weeks
Number of subjects: 184
Study 31142294 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention once a week for 12 weeks
Number of subjects: 184
Study 31142294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 184
Study 31142294 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 184
Study 29621568 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental solution containing NaF/TiF4 (189 ppm Ti+4, 500 ppm F‐, pH 4.4)
Number of subjects: 15
Study 29621568 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial solution containing SnCl2/NaF/AmF (800 ppm Sn+2, 500 ppm F‐, pH 4.5, Elmex®/GABA, positive control)
Number of subjects: 15
Study 29621568 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 15
Study 27697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine 15 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine 30 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg + Methamphetamine 15 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg + Methamphetamine 30 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: COMPARATOR
Intervention: Buspirone 0 mg + Methamphetamine 15 mg
Number of subjects: 10
Study 27697553 — intervention group
Group type: COMPARATOR
Intervention: Buspirone 0 mg + Methamphetamine 30 mg
Number of subjects: 10
Study 27437463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 70
Study 27437463 — intervention group
Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 70
Study 22559200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity stress-management intervention (first step for all patients)
Number of subjects: 300
Study 22559200 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive stress-management intervention (group setting or individually)
Number of subjects: 300
Study 22559200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of the intervention
Number of subjects: 300
Study 21298840 — intervention group
Group type: EXPERIMENTAL
Intervention: Centella asiatica extract capsule (50 mg of extracted asiaticoside per capsule, 2 capsules after meals, three times a day)
Number of subjects: 200
Study 21298840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17682639 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% potassium nitrate/20% benzocaine/10% tetracaine/aqueous hydroxyethyl cellulose gel
Number of subjects: 100
Study 17682639 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl cellulose without active agents
Number of subjects: 100
Study 16091398 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection
Number of subjects: 207
Study 16091398 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 207
Study 16091398 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection and Physiotherapy
Number of subjects: 207
Study 12401641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone 30 mg (T30 group)
Number of subjects: 90
Study 12401641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 90
Study 12401641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone 10 mg (T10 group)
Number of subjects: 90
Study 10091630 — intervention group
Group type: EXPERIMENTAL
Intervention: One piribedil patch (1 PP)
Number of subjects: 27
Study 10091630 — intervention group
Group type: EXPERIMENTAL
Intervention: Two piribedil patches (2 PP)
Number of subjects: 27
Study 10091630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7792499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic naps (0, 2, 4 or 8 hours)
Number of subjects: 140
Study 7792499 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400-mg dose of caffeine
Number of subjects: 140
Study 7792499 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of caffeine (150 or 300 mg every 6 hours)
Number of subjects: 140
Study 7792499 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no nap and placebo administered every 6 hours)
Number of subjects: 140
Study 2237331 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota model treatment for alcohol abuse
Number of subjects: 0
Study 2237331 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment for alcohol abuse
Number of subjects: 0
Study 327652 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bethanechol chloride 5 mg
Number of subjects: 20
Study 327652 — intervention group
Group type: COMPARATOR
Intervention: Oral bethanechol chloride 100 mg
Number of subjects: 20
Study 327652 — intervention group
Group type: COMPARATOR
Intervention: Oral bethanechol chloride 200 mg
Number of subjects: 20
Study 30860573 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus AKT inhibitor capivasertib
Number of subjects: 59
Study 30860573 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 59
Study 30860573 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (capivasertib and placebo)
Number of subjects: 59
Study 29149912 — intervention group
Group type: EXPERIMENTAL
Intervention: UC with process incentive
Number of subjects: 240
Study 29149912 — intervention group
Group type: EXPERIMENTAL
Intervention: UC with outcome incentive
Number of subjects: 240
Study 29149912 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) only
Number of subjects: 240
Study 24408035 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ω‐3
Number of subjects: 60
Study 24408035 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 60
Study 24320057 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen with anti-inflammatory agents starting on the first day after laser treatment.
Number of subjects: 30
Study 24320057 — intervention group
Group type: COMPARATOR
Intervention: Control side treated with petrolatum ointment only.
Number of subjects: 30
Study 22741251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of reinforcing kidney and activating spleen
Number of subjects: 72
Study 22741251 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate D3 tablets (600 mg, twice a day)
Number of subjects: 72
Study 19541657 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-association task
Number of subjects: 0
Study 19541657 — intervention group
Group type: EXPERIMENTAL
Intervention: Word fragment completion task
Number of subjects: 0
Study 17253178 — intervention group
Group type: EXPERIMENTAL
Intervention: ginsenoside Rg3 combined with mitomycin C and tegafur (MF)
Number of subjects: 71
Study 17253178 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C+Tegafur (MF)
Number of subjects: 71
Study 15204148 — intervention group
Group type: EXPERIMENTAL
Intervention: New regimen of fusidic acid suspension (20 mg/kg divided b.i.d.)
Number of subjects: 430
Study 15204148 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of fusidic acid suspension (50 mg/kg divided t.i.d.)
Number of subjects: 430
Study 14615175 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone breast implants (SBI)
Number of subjects: 84
Study 14615175 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 84
Study 11285961 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated CO2
Number of subjects: 40
Study 11285961 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 (Control)
Number of subjects: 40
Study 9451682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpathogenic Escherichia coli strain Nissle 1917
Number of subjects: 0
Study 9451682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7515643 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal nodal irradiation (STNI)
Number of subjects: 770
Study 7515643 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of EBVP (epirubicin, bleomycin, vinblastine, prednisone) followed by involved‐field irradiation (IF‐RT)
Number of subjects: 770
Study 7515643 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of EBVP plus IF‐RT
Number of subjects: 770
Study 7515643 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of MOPP/ABV hybrid plus IF‐RT
Number of subjects: 770
Study 3070936 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet concentrates (lp-PC) stored at 22 degrees C for 1 day
Number of subjects: 31